Cancer/Oncology

A Surprising Finding in Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma

Mark Evans, MD, University of California, Irvine, Orange, CA, USA

“Clonal Selection Following FLT3 Tyrosine Kinase Inhibitor Treatment for Acute Myeloid Leukemia”

Adam Fisch, Brigham and Women's Hospital, Boston, MA, USA

Identification of a Cryptic ABL1 Rearrangement in a Refractory Acute Myeloid Leukemia Patient with Diploid Karyotype by Conventional Cytogenetics

Arash Ronaghy, MD, PhD, MD Anderson Cancer Center, Houston, TX, USA

Muddy Waters: A Report of Granulocytes Infusion Confounding Next-Generation Sequencing Interpretation

Tareq Qdaisat, MD, University of Nebraska Medical Center, Omaha, NE, USA

Compound EGFR and BRAF variants in NSCLC against the backdrop of suspected MEN2A

Jeremy Adler, MD, Pennsylvania Hospital, UPHS, Philadelphia, PA, USA

Expanded Next Generation Sequencing Panel Detects A Rare EGFR Kinase Domain Duplication In A Patient with Metastatic Lung Cancer

Jong Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Pitfalls in Identification of Mismatch Repair Deficiency: An Unusual Pulmonary Intimal Sarcoma.

Wanying Zhang, MD, New York Presbyterian Hospital, New York, NY, USA

EGFR-Mutated Lung Adenocarcinoma with Early Resistance to Osimertinib

Brennan Decker, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia

Ivana Gojo, MD, Johns Hopkins, Baltimore, MD, USA

Choosing Patient Therapy with Dynamic BH3 Profiling

Anthony Letai, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA

Diverse Mechanisms of Acquired Resistance to CAR T Cell Immunotherapy

Andrei Thomas-Tikhonenko, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Clinical Implementation of Pharmacogenomics

Philip Empey, PharmD, PhD, University of Pittsburgh, UPMC, Pittsburg, PA, USA

What’s New in Pharmacogenetics?

Victoria M. Pratt. PhD, Indiana University School of Medicine, Indianapolis, IN, USA

Perspective on Establishing a Biorepository for Clinical and Research Use

Kristy Crooks, PhD, University of Colorado, Aurora, CO, USA

Profiling the DNA Damage Repair Capacity of High Grade Serous Ovarian Tumors using Patient-Derived Organoids

Sarah Hill, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Big Data and Little Patients: Targeted Sequencing for Pediatric Brain Tumors

Sarah Leary, MD, MS, Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Bigger is Better: More Cancer Genes in More Patients

Wendy Chung, MD, PhD, Columbia University, New York, NY, USA

Larissa Furtado, MD, St. Jude Children's Research Hospital, Memphis, TN, USA

David S. Viswanatha, MD, Mayo Clinic and Foundation, Rochester, MN,  USA

Standing of Molecular within the Pathology/Lab Profession

Karen Kaul, MD, PhD, NorthShore University Health System, Evanston, IL, USA

Evolving Technologies and Automation

Karl Voelkerding, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Panel Discussion

Federico Monzon, MD, Castle Biosciences, Friendswood, TX, USA

Aaron Bossler, MD, PhD, University of Iowa, Iowa City, IA, USA

Yaolin Zhou, MD, Univ of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Helen Fernandes, PhD, Columbia University Medical Center, New York, NY, USA

How to Validate Rare Findings - Focus on Novel Fusions

John Iafrate, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

Did I Find the Right Needle in the Haystack? Sensitivity and Specificity Challenges Revealed by Ultra-accurate NGS

Rosana Risques, PhD, UW Pathology, Seattle, WA, USA

Fei Dong, MD, Brigham and Women's Hospital, Boston, MA, USA

B-lymphoblastic Leukemia with ZNF384 Gene Rearrangement

Shweta Bhavsar, MBBs, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Molecular Diagnosis of MDS in a Non-Diagnostic Bone Marrow Specimen

Jeffrey SoRelle, MD, University of Texas Southwestern Medical Center, Dallas, TX, USA

The Role of Lymphoma Sequencing Panel in the Diagnosis of Pediatric-Type Follicular Lymphoma

Guang Yang, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

5q- in a Patient with Chronic Myelogenous Leukemia in Accelerated Phase

James Corines, DO, SUNY Upstate Medical University, Syracuse, NY, USA

Advances in Liquid Biopsy: Isolation, Analysis and Expansion of CTCs

Sunitha Nagrath, PhD, University of Michigan, Ann Arbor, MI, USA

Microfluidic Platforms for the Efficient Isolation of Circulating Leukemia Cells and Circulating Plasma Cells

Steven A. Soper, PhD, The University of Kansas, Lawrence, KS, USA

Advances in Multiple Myeloma Genomics

Brian A. Walker, BSc, PhD, University of Arkansas for Medical Sciences, Little Rock, AR

Molecular Monitoring of Myeloma

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, USA

Genetic Pathways of Myeloid Transformation in Bone Marrow Failure Syndromes

Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

An Interesting Case Involving a CIC-NUTM1 Rearranged Epitheliod Tumor

Latrice Landry, PhD, MMSc, MS, Dana Farber Cancer Institute/ Brigham and Women's Hospital, Boston, MA, USA

Detection of Rare Fusion using Foundation One and Oncomine Tests: A Male in his 20’s with an Aggressive Orbital Tumor

Terri Jones, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

A Case of Cutaneous Lymphoma with PCM1-JAK2 Rearrangement

Talent Theparee, MD, Stanford Healthcare, Stanford, CA, USA

Microsatellites: Instability in an Apparently Stable World

Patrick Leach, BS, TriCore Reference Laboratories, Albuquerque, NM, USA

RNA-seq for the Detection of Gene Fusions and Other Alterations in Cancer

Kevin Halling, MD, PhD, Mayo Clinic, Rochester, MN, USA

Applications of RNA-Seq in Cancer

Olena Vaske, PhD, FCCMG, University of California, Santa Cruz, CA, USA

Approaches to Returning Germline Results in an Era of Agnostic Cancer Predisposition Testing

Michael F. Walsh, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The Evolving Landscape of Clinical Genomic Testing: Elective Genome Sequencing

Birgit Funke, Dr, Veritas Genetics, Newton, MA, USA

What to Expect When You Find the Unexpected: Pregnancy and Incidental Findings in Noninvasive Prenatal Screening

Susan Hancock, MS, Myriad Women's Health, Salt Lake City, UT, USA

Tumor Mutational Burden (TMB): Harmonization and Future Application

Jeff Allen, PhD, Friends of Cancer Research, Washington, DC, USA

TMB: The Case for Understanding and Harmonizing Complex Biomarkers 

Albrecht Stenzinger, MD, University Hospital Heidelberg, Heidelberg, Germany

James Versalovic, MD, PhD, Texas Children's Hospital, Houston, TX, USA

Kevin Halling, MD, PhD, Mayo Clinic, Rochester, MN, USA

Stephen Lincoln, Invitae, San Francisco, CA, USA

H034 - Identification of Neoplastic Clonal T-cell Sequences in Unrelated Healthy Individuals: Limitations of High Throughput TRG Sequencing for Minimal Residual Disease (MRD) Analysis

Siddhartha Sen, MD, PhD, Duke University Medical Center, Durham, NC, USA

H039 - Measurable Residual Disease Monitoring for Patients with Acute Myeloid Leukemia Following Hematopoietic Cell Transplantation Using Error Corrected Hybrid Capture Next Generation Sequencing

Vidya Balagopal, PhD, University of Chicago, Chicago, IL, USA

H021 - IGH locus assessment using hybrid-capture, a proof-of-concept study

Etienne Mahe, MD, MSc, FRCPC, FCAP, University of Calgary, Calgary, Alberta, Canada

H027 - Convergence on Genomic Abrogation of the DNA Damage Response Pathway in CLL is Observed in Patients with Loss of18p

Waihay Wong, Brigham and Women's Hospital and Harvard Medical School

H020 - IDH1 p.S280F mutation is potentially a novel mechanism of resistance to Ivosidenib therapy in an IDH1 positive acute myeloid leukemia

Zoltan Oltvai, MD, University of Pittsburgh, Pittsburgh, PA, USA

ST132 - The Impact of Clinical Molecular Testing and Precision Medicine in Thyroid Cancer

Dora Dias-Santagata, PhD, FACMG, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

ST009 - Improved Detection of MET Exon 14 Skipping Mutations in Lung Adenocarcinoma with Combined DNA/RNA Testing and Refined Analysis Methods

David Manthei, MD, PhD, University of Michigan, Department of Pathology, Ann Arbor, MI, USA

ST010 - Detection of Point Mutations in Paediatric Low Grade Glioma (PLGG) and Diffuse Intrinsic Pontine Glioma (DIPG) Patients: Validation of a Novel Liquid Biopsy Assay

Monique Johnson, MSc, The Hospital for Sick Children, Toronto, Ontario, Canada

ST015 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Fei Huang, Zhongshan Hospital, Fudan University, Shanghai, China

ST094 - STK11 Loss of Function Variants Mediate Immune Evasion in NSCLC via Dysregulation of the FAK/Hippo Signaling Axis and Subsequent Alterations in Tumor-Intrinsic Cytokine Expression

Liam Donnelly, MD, University of Vermont Medical Center, Burlington, VT, USA

TT011 - A Comprehensive Assessment of onco-panel sequencing across multiple laboratories and technologies

Joshua Xu

TT066 - Variants Reported by Tumor-Only Clinical Oncology NGS Testing Are Frequently Found in the Germline of Pediatric Patients

Azhar Saeed, MD, MSc, University of Kansas Medical Center, Kansas City, KS, USA

TT071 - EXaCT-2: Augmented Whole Exome Sequencing Optimized for Clinical Testing in Oncology

Duane Hassane, PhD, Weill Cornell Medicine, New York, NY, USA

TT072 - Dissimilarity score (DisScore): identifying potential discordance between anatomic pathology and mutation landscape in the evaluation of clinical sequencing as part of a molecular tumor board

Grzegorz Gurda, MD, PhD, Gundersen Health System, La Crosse, WI, USA

TT055 - Digital Methylation Specific Multiplex Ligation-Dependent Probe Amplification: A novel MLPA based technique for assessing promoter methylation status in cancer

Jan Smout, MSc, MRC Holland, Amsterdam, Netherlands 

Panel Discussion

Charles Duan, JD, The R Street Institute, Washington, DC, USA
Robert Nussbaum, MD, Invitae, San Francisco, CA, USA
Sandra Park, JD, American Civil Liberties Union, New York, NY, USA
Hans Sauer, JD, Biotechnology Innovation Organization, Washington, DC, USA

MRD in AML - Promises, Problems and Perspectives

Christian Thiede, MD, University of Technics, Dresden, Germany